Perceptive Advisors’s Allogene Therapeutics ALLO Stock Holding History

Perceptive Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,725,000	Closed	-$7.63M	–	101
2024 Q3	$7.63M	Hold	2,725,000	–	–	0.16%	75
2024 Q2	$6.35M	Buy	+2,725,000	New	+$8.04M	0.15%	73
2021 Q2	–	Sell	-1,143,790	Closed	-$40.4M	–	152
2021 Q1	$40.4M	Hold	1,143,790	–	–	0.51%	50
2020 Q4	$28.9M	Hold	1,143,790	–	–	0.31%	65
2020 Q3	$43.1M	Sell	1,143,790 -400,000	-26%	-$15.1M	0.63%	41
2020 Q2	$66.1M	Hold	1,543,790	–	–	1.07%	24
2020 Q1	$30M	Hold	1,543,790	–	–	0.78%	32
2019 Q4	$40.1M	Hold	1,543,790	–	–	0.8%	32
2019 Q3	$42.1M	Hold	1,543,790	–	–	1.13%	25
2019 Q2	$41.5M	Hold	1,543,790	–	–	0.95%	27
2019 Q1	$44.6M	Hold	1,543,790	–	–	1.26%	23
2018 Q4	$41.6M	Buy	+1,543,790	New	+$41M	1.58%	19

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Perceptive Advisors's ALLO Position: Q4 2024 in Review

Perceptive Advisors sold out of Allogene Therapeutics (ALLO) in Q4 2024, closing a stake of 2,725,000 shares — an estimated $7.63M sold.

Perceptive Advisors first reported a position in ALLO in Q4 2018 and held it in 12 quarters. The position peaked at $66.1M in Q2 2020. 174 funds tracked by Wall St. Rank hold ALLO as of Q4 2024.

Perceptive Advisors reported no remaining Allogene Therapeutics position as of Q4 2024 after selling out during the quarter.
Perceptive Advisors sold 2,725,000 Allogene Therapeutics shares in Q4 2024, an estimated $7.63M.
Perceptive Advisors first reported a position in Allogene Therapeutics in Q4 2018 and held it in 12 quarters.
Perceptive Advisors's Allogene Therapeutics position peaked at $66.1M in Q2 2020.
174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2024.

Based on Perceptive Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.